European Journal of Cancer
Volume 46, Issue 2 , Pages 266-269 , January 2010

Mild to moderate liver dysfunction does not require dose reduction of oral or intravenous vinorelbine: Results of a pharmacokinetic study

  • Jos J. Kitzen

      Affiliations

    • Dept. of Medical Oncology, Erasmus University Medical Center, Groene Hilledijk 301, 3075 EA Rotterdam, Netherlands
    • ,
  • Christian Puozzo

      Affiliations

    • Institut de recherche Pierre Fabre, 45, place Abel-Gance, 92654 Boulogne Cedex, France
    • ,
  • Maja J. de Jonge

      Affiliations

    • Dept. of Medical Oncology, Erasmus University Medical Center, Groene Hilledijk 301, 3075 EA Rotterdam, Netherlands
    • Corresponding Author InformationCorresponding author: Tel.: +31 180610450.
    • ,
  • Maud Brandely

      Affiliations

    • Institut de recherche Pierre Fabre, 45, place Abel-Gance, 92654 Boulogne Cedex, France
    • ,
  • Jaap Verweij

      Affiliations

    • Dept. of Medical Oncology, Erasmus University Medical Center, Groene Hilledijk 301, 3075 EA Rotterdam, Netherlands

Received 23 October 2009 ,Accepted 29 October 2009.

References 

  1. Lucas S, Donehouwer R, Rowinsky E. Absolute bioavailability (ABA) and pharmacokinetics (PK) of weekly Navelbine (NVB) liquid-filled soft gelatine capsules at full therapeutic doses in patients with solid tumors. Ann Oncol. 1992;3(Suppl. 1):125
  2. Marty M, Fumoleau P, Adenis A, et al. Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol. 2001;12(11):1643–1649
  3. Queisser W, Doss A, Wander HE, et al. Phase II study of vinorelbine by oral route (in a hard gelatine capsule) for metastatic breast cancer patients. A trial of the phase I/II study group of the Association for Medical Oncology of the German Cancer Society. Onkologie. 1991;14(1):35–39
  4. Baweja M, Suman VJ, Fitch TR, et al. Phase II trial of oral vinorelbine for the treatment of metastatic breast cancer in patients ⩾65 years of age: an NCCTG study. Ann Oncolog. 2006;17:623–629
  5. Gridelli C, Manegold C, Mali P, et al. Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: a multicentre phase II trial. Eur J Cancer. 2004;40:2424–2431
  6. Kanard A, Jatoi A, Castillo R, et al. Oral vinorelbine for the treatment of metastatic non-small cell lung cancer in elderly patients: a phase II trial of efficacy and toxicity. Lung Cancer. 2004;43(3):345–353
  7. Freyer G, Delozier T, Lichinister M, et al. Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol. 2003;21:35–40
  8. Robieux I, Sorio R, Borsatti E, et al. Pharmacokinetics of vinorelbine in patients with liver metastases. Clin Pharmacol Ther. 1996;59(1):32–40
  9. Focan C, Kreutz F, Leroy I, et al. Pharmacokinetics and mass-balance elimination of 3H-vinorelbine following IV and oral administration to patients. Proc AACR. 2001;[Abst. 2064]
  10. Beulz-Riché D, Grudé P, Puozzo C, et al. Characterisation of human cytochrome P450 isoenzymes involved in the metabolism of vinorelbine. Fundam Clin Pharmacol. 2005;19:545–553

PII: S0959-8049(09)00818-1

doi: 10.1016/j.ejca.2009.10.031

European Journal of Cancer
Volume 46, Issue 2 , Pages 266-269 , January 2010

Article Tools